Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- products for treating diabetes and obesity (84.3%);
- hemophilia treatment products (8.4%): mainly injections of protein;
- growth hormones (6%): used for treatment of growth deficiencies in children;
- hormone replacement products (1.3%): used for treatment of the menopause and prevention of osteoporosis.
Net sales are distributed geographically as follows: Europe (19.1%), the United States (47.1%), North America (2.5%), Africa/Asia/Middle East/Oceania (11.5%), China (10.5%), Japan and Korea (5.3%) and Latin America (4%).
Number of employees : 43 258 people.
2018 2019 Delta DKK (in Million) % DKK (in Million) % Diabetes and Obesity Care 93,904 84% 102,840 84.3% +9.52% Biopharm 17,927 16% 19,181 15.7% +7%
2018 2019 Delta DKK (in Million) % DKK (in Million) % United States 54,488 48.7% 57,486 47.1% +5.5% Europe 21,679 19.4% 23,262 19.1% +7.3% Africa, Asia, Middle East & Oceania 12,153 10.9% 14,089 11.5% +15.93% China 11,285 10.1% 12,844 10.5% +13.81% Japan & Korea 5,797 5.2% 6,453 5.3% +11.32% Latin America 4,009 3.6% 4,916 4% +22.62% Canada 2,420 2.2% 2,971 2.4% +22.77%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
20
537,000,000
0
0.0% 0
0.0% 75.1%
Stock B
1
1,812,564,000
1,764,557,450
97.4% 48,000,000
2.6%
Shareholders Novo Nordisk A/S (DK0060534915) Novo Nordisk A/S (US)
Name Equities % Novo Nordisk Fonden 135,764,000
7.49% The Vanguard Group, Inc. 48,666,199
2.68% Norges Bank Investment Management 44,164,903
2.44% Alecta Pension Insurance Mutual 27,085,444
1.49% Novo Nordisk A/S 25,747,394
1.42% BlackRock Fund Advisors 25,259,915
1.39% Fundsmith LLP 21,020,456
1.16% BlackRock Investment Management (UK) Ltd. 17,802,968
0.98% Handelsbanken Fonder AB 15,325,041
0.85% Capital Research & Management Co. (World Investors) 15,088,274
0.83%
Name Equities % Renaissance Technologies LLC 28,709,831
1.58% Fisher Asset Management LLC 15,482,832
0.85% United States Trust Co., NA 13,127,240
0.72% Loomis, Sayles & Co. LP 7,364,857
0.41% Jackson Square Partners LLC 6,639,477
0.37% Folketrygdfondet 5,523,410
0.30% Fayez Sarofim & Co. 5,063,047
0.28% Capital Research & Management Co. (International Investors) 4,777,814
0.26% Cambiar Investors LLC 4,608,255
0.25% Managed Account Advisors LLC 4,537,144
0.25%
Name Equities % Valuation
Novo Nordisk A/S (NOVO B) 25,747,394 1.42% 1,782,067,255 USD NNIT A/S (NNIT) 4,375,000 17.5% 90,839,263 USD Innate Pharma (IPH) 9,817,546 12.4% 37,392,775 USD
-
- Main Market Large
- OMXC 20 / Low Carbon 100 Europe, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200
- Bloomberg Code :
NOVOB:DC
- Reuters Code :
NOVOb.CO
- Datastream Code :
DK:NON
Company contact information
New $1 billion fund aims to steer antibiotic companies in tough market
NOVO NORDISK AS
Sector Pharmaceuticals - NEC
Connections : Novo Nordisk A/S
Canada
Deutschland
France
Schweiz (DE)
United Kingdom
Report
